Skip to main content

CORRECTION article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1516024
This article is part of the Research Topic Integrating Molecular Mechanisms, Immunotherapy, and Drug Sensitivity in Cancer Immunology and Oncology View all 7 articles

Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Provisionally accepted
Mi Meng Mi Meng 1Bo Yu Bo Yu 2Hu Ma Hu Ma 1*Sisi He Sisi He 1*Jie Luo Jie Luo 3Yuju Bai Yuju Bai 1Shi Cheng Chen Shi Cheng Chen 2
  • 1 Department of Thoracic Oncology,The second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China
  • 2 Department of Urology, Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China
  • 3 Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China, Guiyang, China

This article is a correction to:

  1. Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

    1. Read original article

The final, formatted version of the article will be published soon.

    Incorrect Affiliation In the published article, there was an error in affiliation [1]. Instead of “[ Department of Thoracic Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China]”, it should be “[ Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China]”.

    Keywords: Sintilimab, thymic carcinoma(TC), Therapeutic option, case report, anti-PD-1

    Received: 23 Oct 2024; Accepted: 25 Nov 2024.

    Copyright: © 2024 Meng, Yu, Ma, He, Luo, Bai and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hu Ma, Department of Thoracic Oncology,The second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China
    Sisi He, Department of Thoracic Oncology,The second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.